Qilu Pharmaceutical's Romiplostim N01 (RuiliSheng®) Features Five Studies at EHA 2026, Spanning Aplastic Anemia, CTIT, and Stem Cell Transplantation
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
The 31st European Hematology Association (EHA) Congress 2026 will be held from June 11 to 14 in Stockholm, Sweden, in a "virtual + in-person" combined format. As one of the largest and most academically influential events in the global hematology field, this year's congress will attract hematologists, research scholars, and clinicians from around the world.
The official website of the conference shows that five research achievements developed by Qilu Pharmaceutical for the drug Romiplostim N01 (brand name: Ruili Sheng®) have been successfully selected, including three conference posters and two abstracts. The research achievements cover multiple clinical challenge areas, including aplastic anemia (AA), cancer treatment-induced thrombocytopenia (CTIT), and hematopoietic stem cell transplantation.
Abstract Number: PF1117
English Title:Romiplostim N01 for platelet recovery after unrelated umbilical cord blood transplantation in patients with hematological malignancies: A phase II, single-arm study
English Title:A Phase II Single-Arm Clinical Study of Romiplostim N01 for Platelet Recovery in Hematologic Cancer Patients After Unrelated Cord Blood Transplantation
Display Format:Poster
Principal Investigator: Xiaoyu Zhu
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Abstract Number: PF1136
English Title:Romiplostim N01 for promoting platelet engraftment after Allo-HSCT: Interim results of a phase II exploratory trial from NICHE cohort
English Title:Romiplostim N01 for Promoting Platelet Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): Interim Results from a Phase II Exploratory Trial of the NICHE Cohort
Display Format:Poster
Principal Investigator: Erlie Jiang
Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)
Abstract Number: PS1790
English Title:Romiplostim in chemoradiotherapy-associated aplastic anaemia: A prospective single-arm study
English Title:The Application of Romiplostim in Chemotherapy-Induced Aplastic Anemia: A Prospective Single-Arm Study
Display Format:Poster
Principal Investigator: Han Bing
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Abstract Number: PB4293
English Title: A prospective, single-arm study of Romiplostim N01 for platelet engraftment after autologous stem cell transplantation in multiple myeloma
English Title:A Prospective Single-Arm Study Evaluating the Use of Romiplostim N01 for Platelet Engraftment Following Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Display Format:Published online
Principal Investigator: Ge Jian
The First Affiliated Hospital of Anhui Medical University
Abstract Number: PB4298
English Title:Romiplostim N01 as switch therapy in cancer therapy-related thrombocytopenia: A real-world study
English Title:The Application of Romiplostim N01 as Conversion Therapy in Antineoplastic Treatment-Related Thrombocytopenia: A Real-World Study
Display Format:Online Publication
Principal Investigator: Miao Chen
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
The concentrated presentation of Ruilisheng® at this year's EHA conference not only reflects Qilu Pharmaceutical's continued dedication to the field of thrombocytopenia-related diseases but also reaffirms the growing attention and recognition of China-developed/original or biosimilar products in the international hematology community. The release of multiple research data sets is expected to provide new evidence-based support for clinicians in managing complex hematological disorders.
Typesetting Editor: Oncology News-jyy
